Volume 16, Issue 4 p. 359-365
Perspective

Data mining for signals in spontaneous reporting databases: proceed with caution

Wendy P. Stephenson MD, MS, MPH,

Corresponding Author

Wendy P. Stephenson MD, MS, MPH

Wendy Stephenson & Associates LLC, Maple Glen, PA, USA

Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, USA

Wendy Stephenson & Associates LLC, Expertise in Pharmaceutical Safety, 1816 Carmel Place, Maple Glen, PA 19002, USA.Search for more papers by this author
Manfred Hauben MD, MPH,

Manfred Hauben MD, MPH

Risk Management Strategy, Pfizer Inc., New York, NY, USA

Department of Medicine, New York University School of Medicine, NY, USA

Departments of Pharmacology and Community And Preventive Medicine, New York Medical College, Valhalla, NY, USA

Search for more papers by this author
First published: 03 October 2006
Citations: 80

No conflict of interest was declared.

Abstract

Purpose

To provide commentary and points of caution to consider before incorporating data mining as a routine component of any Pharmacovigilance program, and to stimulate further research aimed at better defining the predictive value of these new tools as well as their incremental value as an adjunct to traditional methods of post-marketing surveillance.

Methods/Results

Commentary includes review of current data mining methodologies employed and their limitations, caveats to consider in the use of spontaneous reporting databases and caution against over-confidence in the results of data mining.

Conclusions

Future research should focus on more clearly delineating the limitations of the various quantitative approaches as well as the incremental value that they bring to traditional methods of pharmacovigilance. Copyright © 2006 John Wiley & Sons, Ltd.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.